Statistical significance has been reached on the primary variable. The successful result of the study will be published under R&D|Studies.
We are happy to announce that the new issue of shares was oversubscribed. The raised capital finances the company’s activities for 18 months. The activities include finishing the clinical studies and CE-marking of our products. For more information contact the Chairman of the board, Jonas Tilly.
Novosense completes private placement of new shares. Read More »
The partners in this project are Tyndall National Institute , Fraunhof-EMFT, CNRS, UCC, Analog Devices and Novosense. The goal is to develop a smart cardiac monitoring patch, ‘SmartVista’, powered by body heat for the digital health care sector. For more information, please see R&D|Research.
Novosense and partners are awarded € 4 million in EU Horizon ICT programme. Read More »
